Conatus Pharmaceuticals (CNAT) Shares Pop Higher on Positive Zika Virus Mention
- Stocks close with gains, led by Dow as investors look for rate insight
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Robinhood (HOOD) rises after saying it plans to launch a credit card for US consumers
- Short sellers target Reddit shares as stock slips
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Conatus Pharmaceuticals (CNAT) Gains on WSJ Zika-Related Mention
August 29, 2016 11:58 AM EDTConatus Pharmaceuticals (NASDAQ: CNAT) surges following WSJ mention related to Zika. Shares up 15%.
The article discusses liver-disease drug emricasan for use to quell the Zika virus, which Conatus holds several patents on.
... More